Unknown

Dataset Information

0

Generation of healthy mice from gene-corrected disease-specific induced pluripotent stem cells.


ABSTRACT: Using the murine model of tyrosinemia type 1 (fumarylacetoacetate hydrolase [FAH] deficiency; FAH?/? mice) as a paradigm for orphan disorders, such as hereditary metabolic liver diseases, we evaluated fibroblast-derived FAH?/?-induced pluripotent stem cells (iPS cells) as targets for gene correction in combination with the tetraploid embryo complementation method. First, after characterizing the FAH?/? iPS cell lines, we aggregated FAH?/?-iPS cells with tetraploid embryos and obtained entirely FAH?/?-iPS cell-derived mice that were viable and exhibited the phenotype of the founding FAH?/? mice. Then, we transduced FAH cDNA into the FAH?/?-iPS cells using a third-generation lentiviral vector to generate gene-corrected iPS cells. We could not detect any chromosomal alterations in these cells by high-resolution array CGH analysis, and after their aggregation with tetraploid embryos, we obtained fully iPS cell-derived healthy mice with an astonishing high efficiency for full-term development of up to 63.3%. The gene correction was validated functionally by the long-term survival and expansion of FAH-positive cells of these mice after withdrawal of the rescuing drug NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione). Furthermore, our results demonstrate that both a liver-specific promoter (transthyretin, TTR)-driven FAH transgene and a strong viral promoter (from spleen focus-forming virus, SFFV)-driven FAH transgene rescued the FAH-deficiency phenotypes in the mice derived from the respective gene-corrected iPS cells. In conclusion, our data demonstrate that a lentiviral gene repair strategy does not abrogate the full pluripotent potential of fibroblast-derived iPS cells, and genetic manipulation of iPS cells in combination with tetraploid embryo aggregation provides a practical and rapid approach to evaluate the efficacy of gene correction of human diseases in mouse models.

SUBMITTER: Wu G 

PROVIDER: S-EPMC3134447 | biostudies-literature | 2011 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications


Using the murine model of tyrosinemia type 1 (fumarylacetoacetate hydrolase [FAH] deficiency; FAH⁻/⁻ mice) as a paradigm for orphan disorders, such as hereditary metabolic liver diseases, we evaluated fibroblast-derived FAH⁻/⁻-induced pluripotent stem cells (iPS cells) as targets for gene correction in combination with the tetraploid embryo complementation method. First, after characterizing the FAH⁻/⁻ iPS cell lines, we aggregated FAH⁻/⁻-iPS cells with tetraploid embryos and obtained entirely F  ...[more]

Similar Datasets

| S-EPMC7227215 | biostudies-literature
| S-EPMC2720823 | biostudies-literature
| S-EPMC9768576 | biostudies-literature
| S-EPMC2633781 | biostudies-literature
| S-EPMC3340557 | biostudies-literature
| S-EPMC4682065 | biostudies-literature
| S-EPMC3978583 | biostudies-literature
| S-EPMC3392774 | biostudies-other
| S-EPMC5031952 | biostudies-literature
| S-EPMC3981863 | biostudies-literature